Efficacy of Icotinib treatment in patients with stage IIIb/IV non‐small cell lung cancer

Abstract

Background: To evaluate the efficacy and safety of Icotinib -an orally administered, highly potent selective inhibitor of epidermal growth factor receptor (EGFR) and its active mutations, in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 101 patients with stage IIIb/IV NSCLC were treated with 125 mg Icotinib three times a day until disease progression or intolerable toxicity. Response rate was evaluated using response evaluation criteria in solid tumors and progression-free survival (PFS) was collected. Results: The overall response rate (ORR) and disease control rate (DCR) were 37.6% (38/101) and 79.2% (80/101), respectively. The median PFS was 6.5 months. Multivariate analysis showed that female gender (P = 0.048, 95% confidence interval [CI] 1.010-6.016) and occurrence of rash (P = 0.002, 95% CI 1.667-9.809) were the independent predictive factors for ORR, while a performance status (PS) score of 0-1 (P = 0.001, 95% CI 0.024-0.402) and rash (P = 0.042, 95% CI 1.089-76.557) were the independent predictive factors for DCR. In addition, PS scores of 0-1 (P < 0.001, 95% CI 0.135-0.509), and non-smoking (P = 0.017, 95% CI 0.342-0.900) were found to be independent influencing factors for PFS. Moreover, patients with EGFR mutations had better PFS than patients with wild type EGFR, while patients with EGFR exon 19 deletion had better survival than those with EGFR exon 21 mutation. The most common adverse effects of Icotinib were rash (35.6%) and diarrhea (17.8%), which was tolerable. Conclusion: Treatment of stage IIIb/IV NSCLC patients with Icotinib was effective and tolerable, specifically in patients with EGFR mutation.

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies

“…Seven studies [14–18, 20, 22, 24] concerning the relationship between the PFS and prior chemotherapy showed that the PFS of first line group (10.1 months) and the second line (7.1 months) did not have a statistical difference when they received icotinib ( t = 1.59, df = 12, p = 0.13) (Figure 3D). …”

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report

“…Several phase I and II studies of icotinib in treatment of BM have been published recently. Zhou et al reported that icotinib could be well tolerated at dose of 375mg tid/day concurrent with WBRT in a phase I study, and found that the mean icotinib cerebrospinal fluid (CSF) penetration rate was 4.04% (range: 1.23%–9.71%) [ 22 ]. A phase II study of icotinib combined with WBRT treatment found that the CSF concentration and penetration rate were 11.6 ± 9.1 ng/mL and 1.4 ± 1.1% respectively at a dose of icotinib 125mg tid.…”

Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo

“…The efficacy of chemotherapy and the radiotherapy for non-small cell lung carcinoma tends to be low, and surgical resection of cancer is mainly applied for patients in early stage non-small cell lung carcinoma (1-3). Combination chemotherapy is carried out in addition to the surgical resection of cancer for an advanced non-small cell lung carcinoma (1,(3)(4). The main anti-cancer drug in chemotherapy for non-small cell lung carcinoma is cisplatin (1,3).…”

“…Combination chemotherapy is carried out in addition to the surgical resection of cancer for an advanced non-small cell lung carcinoma (1,(3)(4). The main anti-cancer drug in chemotherapy for non-small cell lung carcinoma is cisplatin (1,3). Cisplatin-combination chemotherapy use irinotecan, paclitaxel, gemcitabine and vinorelbine (1,3).…”

“…The main anti-cancer drug in chemotherapy for non-small cell lung carcinoma is cisplatin (1,3). Cisplatin-combination chemotherapy use irinotecan, paclitaxel, gemcitabine and vinorelbine (1,3). Because combination chemotherapy may be accompanied with severe side-effects (1, 3), anticancer drugs without side effects for the patients with lung carcinoma are desired.…”